meta|Evidence - COVID-19
Member of the meta|Evidence galaxy
Treament | Trials | auto | |||
---|---|---|---|---|---|
symptomatic Covid-19 | severe COVID-19 occurrence | serologic response (seroconversion) | |||
|
9 | -25 [-27; -22] /10000 17/65360 vs. 727/266156 | -21 [-29; -14] /10000 0/14134 vs. 30/14073 | - | |
|
39 | -121 [-126; -116] /10000 67/78038 vs. 3581/276063 | -1 [-3; 1] /10000 1/21314 vs. 4/21259 | - | |
|
19 | -191 [-232; -150] /10000 84/8597 vs. 248/8580 | -1 [-3; 1] /10000 0/12021 vs. 1/11724 | - | |
|
9 | -119 [-140; -97] /10000 116/19514 vs. 348/19544 | -24 [-32; -15] /10000 14/19514 vs. 60/19544 | - |
Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant
149
treatments |
718
studies with results |
1743
studies screend |
1629
references |
This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N), Université de Lyon (UdL/Idex), and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.
![]() |
![]() |
![]() |
![]() |
-
About
-
Our approach
-
Credits
-
RSS
Made with in Lyon
-
Contact us
-
Privacy policy
-